Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510104 | 1.00 | GRM4 (1.00) | GRM4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL179801 | 1.00 | GRM4 (1.00) | GRM4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4712658 | 0.87 | RAB9A (0.76) | GRM4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4711247 | 0.86 | KDM4E (0.76) | GRM4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4711246 | 0.86 | KDM4E (0.76) | GRM4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL10665839 | 0.85 | GRM4 (0.73) | GRM4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL10665836 | 0.85 | GRM4 (0.73) | GRM4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4712490 | 0.85 | NPC1 (0.73) | GRM4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4711058 | 0.85 | NPC1 (0.73) | GRM4KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4711084 | 0.83 | ALDH1A1 (0.71) | GRM4KDM4EALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285637-A1 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | The Royal Institution of the Advancement of Learning/McGill University (CA) | 2024-08-29 | — | — | US | claimed |
| EP-4366739-A1 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2024-05-15 | — | — | EP | claimed |
| WO-2023279193-A9 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-04-27 | — | — | WO | claimed |
| WO-2023279193-A2 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-01-12 | — | — | WO | claimed |
| US-20130225623-A1 | Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2013-08-29 | — | — | US | claimed |
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-16 | — | — | US | claimed |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-15 | — | — | US | claimed |
| US-20110263652-A1 | Treatment and/or Prevention of Inner Ear Conditions by Modulation of a Metabotropic Glutamate Receptor | HOUSE EAR INSTITUTE (US) | 2011-10-27 | — | — | US | claimed |
| EP-2344151-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2011053636-A1 | METHODS OF TREATING PSYCHIATRIC OR NEUROLOGICAL DISORDERS WITH MGLUR ANTAGONISTS | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2011-05-05 | — | — | WO | claimed |
| US-20040215284-A1 | Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists | RECORDATI S.A. | 2004-10-28 | — | — | US | claimed |
| WO-2004067002-A2 | SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT | RECORDATI IRELAND LIMITED (IE) | 2004-08-12 | — | — | WO | claimed |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY RESEARCH FOUNDATION (BURF) (US) | 2004-04-08 | — | — | US | claimed |
| EP-1392363-A2 | COMPOSITIONS AND USES OF MGLUR5 ANTAGONISTS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 2004-03-03 | — | — | EP | claimed |
| JP-2003528136-A | — | — | 2003-09-24 | — | — | JP | claimed |
| US-20030109504-A1 | Treatment of movement disorders with metabotropic glutamate receptors antagonist | MOTAC NEUROSCIENCE LIMITED (GB) | 2003-06-12 | — | — | US | claimed |
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-29 | — | — | US | claimed |
| EP-1274417-A2 | TREATMENT OF MOVEMENT DISORDERS WITH METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | Motac Neuroscience Limited (GB) | 2003-01-15 | — | — | EP | claimed |
| WO-2002078745-A2 | USE OF MGLUR5 ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF AUTISM, MENTAL RETARDATION, SCHIZOPHRENIA | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2001072291-A2 | TREATMENT OF MOVEMENT DISORDERS WITH METABOTROPIC GLUTAMATE RECEPTOR ANTAGONIST | THE VICTORIA UNIVERSITY OF MANCHESTER (GB) | 2001-10-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | GRM5, GRIK5, GRIN1 | GRM4 13/4885KDM4E 2848/4885ALDH1A1 3621/4885 |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | GRM4 4/4885KDM4E 2553/4885ALDH1A1 3762/4885 |
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | GRM4 4/4885KDM4E 2553/4885ALDH1A1 3762/4885 |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | GRM5, GRIK5, GRM2 | GRM4 7/4885KDM4E 1203/4885ALDH1A1 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.